New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma
The FDA approved acalabrutinib as a frontline option for untreated mantle cell lymphoma.
Supreme Court upholds ACA preventive services mandate
The high court preserved a key portion of the Affordable Care Act that requires private insurers to cover a range of…
Patrick Conway to take over CEO duties at Optum Health
Dr. Patrick Conway, who was named CEO of Optum in May, is also taking on the position of leading Optum…
Shifting Therapeutic Urgency and TKI Strategy
An expert discusses how different tyrosine kinase inhibitor (TKI) mechanisms of action, including asciminib’s allosteric binding vs traditional ATP-competitive inhibitors,…
Chronic IVIG Therapy May Reduce Incidence of Cancer, Especially in Patients With CIDP
Intravenous immunoglobulin (IVIG) use over an extended period in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) was potentially associated with…
NCCN Guidelines and Early Response Monitoring in Chronic Myeloid Leukemia
An expert discusses how National Comprehensive Cancer Network (NCCN) guidelines recommend first-line chronic myeloid leukemia (CML) treatments including imatinib, nilotinib,…
Oncology Trials with Flatiron Health – Life Sciences Today Podcast Episode 15
We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest…
CPKC to remedy service disruptions impacting dwell times, switches
While the railroad stated it’s “too early to offer firm predications” for a full return to service, it expects operations…
Optum rolls out AI Marketplace
UnitedHealth Group subsidiary Optum is launching AI Marketplace, a healthcare-specific artificial intelligence platform that’s meant to accelerate AI adoption among…
Correct Patient Misconceptions Around Biosimilars
Some patients incorrectly believe that biosimilars compromise safety or efficacy.